$ANIP
ANI Pharmaceuticals Inc

2017 Q1 Form 10-Q Financial Statement

#000114420417024566 Filed on May 04, 2017

View on sec.gov

Income Statement

Concept 2017 Q1 2016 Q1
Revenue $36.63M $20.56M
YoY Change 78.2% 9.34%
Cost Of Revenue $16.39M $3.410M
YoY Change 380.53% 23.95%
Gross Profit $20.24M $17.15M
YoY Change 18.06% 6.84%
Gross Profit Margin 55.26% 83.41%
Selling, General & Admin $7.293M $5.904M
YoY Change 23.53% 24.27%
% of Gross Profit 36.03% 34.44%
Research & Development $1.618M $966.0K
YoY Change 67.49% 139.7%
% of Gross Profit 7.99% 5.63%
Depreciation & Amortization $6.706M $4.609M
YoY Change 45.5% 247.32%
% of Gross Profit 33.13% 26.88%
Operating Expenses $8.911M $6.870M
YoY Change 29.71% 33.29%
Operating Profit $4.625M $5.666M
YoY Change -18.37% -40.78%
Interest Expense -$2.932M -$2.782M
YoY Change 5.39% 2.09%
% of Operating Profit -63.39% -49.1%
Other Income/Expense, Net -$18.00K $2.000K
YoY Change -1000.0% -97.06%
Pretax Income $1.675M $2.886M
YoY Change -41.96% -58.23%
Income Tax -$523.0K -$1.540M
% Of Pretax Income -31.22% -53.36%
Net Earnings $1.152M $1.346M
YoY Change -14.41% -69.19%
Net Earnings / Revenue 3.15% 6.55%
Basic Earnings Per Share $0.10 $0.12
Diluted Earnings Per Share $0.10 $0.12
COMMON SHARES
Basic Shares Outstanding 11.53M shares 11.40M shares
Diluted Shares Outstanding 11.65M shares 11.49M shares

Balance Sheet

Concept 2017 Q1 2016 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $10.80M $77.70M
YoY Change -86.1% -53.08%
Cash & Equivalents $10.83M $77.75M
Short-Term Investments
Other Short-Term Assets $3.600M $1.300M
YoY Change 176.92% -86.02%
Inventory $45.90M $13.90M
Prepaid Expenses
Receivables $46.70M $22.50M
Other Receivables $0.00 $1.100M
Total Short-Term Assets $107.0M $116.6M
YoY Change -8.23% -42.56%
LONG-TERM ASSETS
Property, Plant & Equipment $12.90M $8.400M
YoY Change 53.57% 59.06%
Goodwill $1.838M
YoY Change 0.0%
Intangibles $147.4M
YoY Change 224.58%
Long-Term Investments
YoY Change
Other Assets $32.00M $17.40M
YoY Change 83.91% 65.71%
Total Long-Term Assets $250.1M $175.0M
YoY Change 42.92% 177.79%
TOTAL ASSETS
Total Short-Term Assets $107.0M $116.6M
Total Long-Term Assets $250.1M $175.0M
Total Assets $357.1M $291.6M
YoY Change 22.47% 9.63%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.800M $3.040M
YoY Change 57.89% 32.87%
Accrued Expenses $18.20M $1.727M
YoY Change 953.85% -8.96%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $32.40M $16.20M
YoY Change 100.0% 78.55%
LONG-TERM LIABILITIES
Long-Term Debt $152.5M $115.2M
YoY Change 32.38% 2.67%
Other Long-Term Liabilities $0.00
YoY Change
Total Long-Term Liabilities $152.5M $115.2M
YoY Change 32.38% 2.67%
TOTAL LIABILITIES
Total Short-Term Liabilities $32.40M $16.20M
Total Long-Term Liabilities $152.5M $115.2M
Total Liabilities $184.9M $131.4M
YoY Change 40.7% 8.38%
SHAREHOLDERS EQUITY
Retained Earnings -$5.504M
YoY Change -64.16%
Common Stock $1.000K
YoY Change 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $172.2M $160.2M
YoY Change
Total Liabilities & Shareholders Equity $357.1M $291.6M
YoY Change 22.47% 9.63%

Cashflow Statement

Concept 2017 Q1 2016 Q1
OPERATING ACTIVITIES
Net Income $1.152M $1.346M
YoY Change -14.41% -69.19%
Depreciation, Depletion And Amortization $6.706M $4.609M
YoY Change 45.5% 247.32%
Cash From Operating Activities $6.529M $10.97M
YoY Change -40.48% 879.38%
INVESTING ACTIVITIES
Capital Expenditures $2.138M $1.369M
YoY Change 56.17% 1122.32%
Acquisitions
YoY Change
Other Investing Activities -$50.96M -$84.18M
YoY Change -39.46%
Cash From Investing Activities -$53.09M -$85.55M
YoY Change -37.94% 1754.97%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00 $2.500M
YoY Change -100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $30.03M -$2.355M
YoY Change -1374.95% -13183.33%
NET CHANGE
Cash From Operating Activities $6.529M $10.97M
Cash From Investing Activities -$53.09M -$85.55M
Cash From Financing Activities $30.03M -$2.355M
Net Change In Cash -$16.54M -$76.94M
YoY Change -78.5% 2114.65%
FREE CASH FLOW
Cash From Operating Activities $6.529M $10.97M
Capital Expenditures $2.138M $1.369M
Free Cash Flow $4.391M $9.600M
YoY Change -54.26% 852.38%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2017Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2016Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
5002000 USD
CY2016Q4 us-gaap Other Accrued Liabilities Noncurrent
OtherAccruedLiabilitiesNoncurrent
625000 USD
CY2016Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
2398000 USD
CY2016Q4 anip Accrued Government Rebates
AccruedGovernmentRebates
5891000 USD
CY2017Q1 us-gaap Revenues
Revenues
36628000 USD
CY2017Q1 us-gaap Cost Of Revenue
CostOfRevenue
16386000 USD
CY2017Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1618000 USD
CY2017Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
7293000 USD
CY2017Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
6706000 USD
CY2017Q1 us-gaap Costs And Expenses
CostsAndExpenses
32003000 USD
CY2017Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
4625000 USD
CY2017Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-2932000 USD
CY2017Q1 us-gaap Net Income Loss
NetIncomeLoss
1152000 USD
CY2017Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
1675000 USD
CY2017Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
523000 USD
CY2017Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.1
CY2017Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.1
CY2017Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11527000 shares
CY2017Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11653000 shares
CY2017Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-18000 USD
CY2017Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1386000 USD
CY2016Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1105000 USD
CY2017Q1 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
1882000 USD
CY2016Q1 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
1725000 USD
CY2017Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
802000 USD
CY2016Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
549000 USD
CY2017Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
2810000 USD
CY2016Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
535000 USD
CY2017Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
25000 USD
CY2016Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-201000 USD
CY2017Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1318000 USD
CY2016Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
889000 USD
CY2017Q1 anip Increase Decrease In Accrued Compensation Liabilities
IncreaseDecreaseInAccruedCompensationLiabilities
-496000 USD
CY2016Q1 anip Increase Decrease In Accrued Compensation Liabilities
IncreaseDecreaseInAccruedCompensationLiabilities
-466000 USD
CY2017Q1 us-gaap Increase Decrease In Income Taxes
IncreaseDecreaseInIncomeTaxes
1258000 USD
CY2016Q1 us-gaap Increase Decrease In Income Taxes
IncreaseDecreaseInIncomeTaxes
-23000 USD
CY2017Q1 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
1161000 USD
CY2016Q1 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
1110000 USD
CY2017Q1 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
50956000 USD
CY2016Q1 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
84182000 USD
CY2017Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2138000 USD
CY2016Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1369000 USD
CY2017Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
25000 USD
CY2016Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
144000 USD
CY2017Q1 us-gaap Excess Tax Benefit From Share Based Compensation Financing Activities
ExcessTaxBenefitFromShareBasedCompensationFinancingActivities
0 USD
CY2016Q1 us-gaap Excess Tax Benefit From Share Based Compensation Financing Activities
ExcessTaxBenefitFromShareBasedCompensationFinancingActivities
1000 USD
CY2017Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
4000 USD
CY2016Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
1643000 USD
CY2017Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
78000 USD
CY2016Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
85000 USD
CY2017Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
6529000 USD
CY2016Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
10969000 USD
CY2017Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-53094000 USD
CY2016Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-85551000 USD
CY2017Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
30025000 USD
CY2016Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-2355000 USD
CY2017Q1 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
0 USD
CY2016Q1 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
2500000 USD
CY2017Q1 us-gaap Increase Decrease In Royalties Payable
IncreaseDecreaseInRoyaltiesPayable
-2250000 USD
CY2016Q1 us-gaap Increase Decrease In Royalties Payable
IncreaseDecreaseInRoyaltiesPayable
2827000 USD
CY2017Q1 us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
-735000 USD
CY2016Q1 us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
-81000 USD
CY2017Q1 anip Increase Decrease In Returned Goods Reserve
IncreaseDecreaseInReturnedGoodsReserve
20000 USD
CY2016Q1 anip Increase Decrease In Returned Goods Reserve
IncreaseDecreaseInReturnedGoodsReserve
18000 USD
CY2017Q1 anip Increase Decrease Accrued Government Rebates
IncreaseDecreaseAccruedGovernmentRebates
-1236000 USD
CY2016Q1 anip Increase Decrease Accrued Government Rebates
IncreaseDecreaseAccruedGovernmentRebates
-1207000 USD
CY2017Q1 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
143750000 USD
CY2017Q1 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
18997000 USD
CY2017Q1 us-gaap Long Term Debt
LongTermDebt
122501000 USD
CY2016Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
143750000 USD
CY2016Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
20644000 USD
CY2016Q4 us-gaap Long Term Debt
LongTermDebt
120643000 USD
CY2017Q1 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
2252000 USD
CY2016Q4 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
2463000 USD
CY2017Q1 us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
1078000 USD
CY2016Q1 us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
1078000 USD
CY2017Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
1647000 USD
CY2016Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
1562000 USD
CY2017Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
211000 USD
CY2016Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
211000 USD
CY2017Q1 us-gaap Interest Costs Capitalized Adjustment
InterestCostsCapitalizedAdjustment
90000 USD
CY2016Q1 us-gaap Interest Costs Capitalized Adjustment
InterestCostsCapitalizedAdjustment
47000 USD
CY2017Q1 us-gaap Inventory Raw Materials
InventoryRawMaterials
17480000 USD
CY2016Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
14138000 USD
CY2017Q1 us-gaap Retail Related Inventory Packaging And Other Supplies
RetailRelatedInventoryPackagingAndOtherSupplies
1078000 USD
CY2016Q4 us-gaap Retail Related Inventory Packaging And Other Supplies
RetailRelatedInventoryPackagingAndOtherSupplies
930000 USD
CY2017Q1 us-gaap Inventory Finished Goods
InventoryFinishedGoods
26990000 USD
CY2016Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
10812000 USD
CY2017Q1 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
260000 USD
CY2016Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
174000 USD
CY2017Q1 us-gaap Inventory Work In Process
InventoryWorkInProcess
605000 USD
CY2017Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
5704000 USD
CY2017Q1 us-gaap Depreciation
Depreciation
300000 USD
CY2017Q1 us-gaap Interest Costs Capitalized
InterestCostsCapitalized
100000 USD
CY2016Q1 us-gaap Interest Costs Capitalized
InterestCostsCapitalized
47000 USD
CY2017Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
6400000 USD
CY2016Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
4400000 USD
CY2017Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
203459000 USD
CY2017Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
26825000 USD
CY2017Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
26825000 USD
CY2017Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
26343000 USD
CY2017Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
24898000 USD
CY2017Q1 us-gaap Finite Lived Intangible Assets Amortization Expense After Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
78231000 USD
CY2017Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
20337000 USD
CY2017Q1 dei Document Type
DocumentType
10-Q
CY2017Q1 dei Amendment Flag
AmendmentFlag
false
CY2017Q1 dei Document Period End Date
DocumentPeriodEndDate
2017-03-31
CY2017Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2017
CY2017Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2017Q1 dei Entity Registrant Name
EntityRegistrantName
ANI PHARMACEUTICALS INC
CY2017Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001023024
CY2017Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2017Q1 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2017Q1 dei Trading Symbol
TradingSymbol
ANIP
CY2017Q1 us-gaap Long Term Line Of Credit
LongTermLineOfCredit
30000000 USD
CY2016Q4 us-gaap Long Term Line Of Credit
LongTermLineOfCredit
0 USD
CY2017Q1 us-gaap Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
29481000 USD
CY2016Q4 us-gaap Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
31535000 USD
CY2017Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2016Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2017Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1666667 shares
CY2016Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1666667 shares
CY2017Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2016Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2016Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2017Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2017Q1 us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
30000000 USD
CY2016Q1 us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
0 USD
CY2017Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-16540000 USD
CY2016Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-76937000 USD
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
154684000 USD
CY2016Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
77747000 USD
CY2017Q1 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
126000 shares
CY2016Q1 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
94000 shares
CY2017Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4600000 shares
CY2016Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4500000 shares
CY2016Q1 us-gaap Interest Expense Debt
InterestExpenseDebt
2804000 USD
CY2017Q1 us-gaap Interest Expense Debt
InterestExpenseDebt
2846000 USD
CY2017Q1 us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
30000000 USD
CY2017Q1 us-gaap Line Of Credit Facility Maximum Borrowing Capacity
LineOfCreditFacilityMaximumBorrowingCapacity
40000000 USD
CY2017Q1 us-gaap Line Of Credit
LineOfCredit
30000000 USD
CY2017Q1 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
1152000 USD
CY2016Q1 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
1346000 USD
CY2017Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
1141000 USD
CY2016Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
1339000 USD
CY2017Q1 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
1141000 USD
CY2016Q1 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
1339000 USD
CY2017Q1 us-gaap Inventory Gross
InventoryGross
46153000 USD
CY2016Q4 us-gaap Inventory Gross
InventoryGross
26357000 USD
CY2017Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
18601000 USD
CY2016Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
16385000 USD
CY2017Q1 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
238048000 USD
CY2017Q1 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
34589000 USD
CY2016Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
203992000 USD
CY2016Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
28200000 USD
CY2017Q1 anip Acquired Finitelived Intangible Asset Amortization Description
AcquiredFinitelivedIntangibleAssetAmortizationDescription
we are amortizing 80% of the value of the intangible assets over the first five years of useful lives of the assets and amortizing the remaining 20% of the value of the intangible assets over the second five years of useful lives of the assets.
CY2016Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1105000 USD
CY2017Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1371000 USD
CY2017Q1 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
300000 USD
CY2016Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
300000 USD
CY2016Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.534 pure
CY2017Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.312 pure
CY2016Q1 anip Accrued Royalties Related To Asset Purchase
AccruedRoyaltiesRelatedToAssetPurchase
1199000 USD
CY2017Q1 anip Accrued Royalties Related To Asset Purchase
AccruedRoyaltiesRelatedToAssetPurchase
0 USD
CY2017Q1 us-gaap Fair Value Inputs Discount Rate
FairValueInputsDiscountRate
0.15 pure
CY2016Q4 anip Cash And Cash Equivalents And Restricted Cash And Cash Equivalents Current And Noncurrent
CashAndCashEquivalentsAndRestrictedCashAndCashEquivalentsCurrentAndNoncurrent
32367000 USD
CY2015Q4 anip Cash And Cash Equivalents And Restricted Cash And Cash Equivalents Current And Noncurrent
CashAndCashEquivalentsAndRestrictedCashAndCashEquivalentsCurrentAndNoncurrent
154684000 USD
CY2017Q1 anip Cash And Cash Equivalents And Restricted Cash And Cash Equivalents Current And Noncurrent
CashAndCashEquivalentsAndRestrictedCashAndCashEquivalentsCurrentAndNoncurrent
15827000 USD
CY2016Q1 anip Cash And Cash Equivalents And Restricted Cash And Cash Equivalents Current And Noncurrent
CashAndCashEquivalentsAndRestrictedCashAndCashEquivalentsCurrentAndNoncurrent
77747000 USD
CY2015Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
0 USD
CY2016Q1 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
0 USD
CY2017Q1 anip Percentage Of Royalties On Net Sales Of Unapproved Products
PercentageOfRoyaltiesOnNetSalesOfUnapprovedProducts
less than 1%
CY2016Q1 anip Percentage Of Royalties On Net Sales Of Unapproved Products
PercentageOfRoyaltiesOnNetSalesOfUnapprovedProducts
less than 1%

Files In Submission

Name View Source Status
0001144204-17-024566-index-headers.html Edgar Link pending
0001144204-17-024566-index.html Edgar Link pending
0001144204-17-024566.txt Edgar Link pending
0001144204-17-024566-xbrl.zip Edgar Link pending
anip-20170331.xml Edgar Link completed
anip-20170331.xsd Edgar Link pending
anip-20170331_cal.xml Edgar Link unprocessable
anip-20170331_def.xml Edgar Link unprocessable
anip-20170331_lab.xml Edgar Link unprocessable
anip-20170331_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
v464832_10q.htm Edgar Link pending
v464832_ex10-1.htm Edgar Link pending
v464832_ex10-2.htm Edgar Link pending
v464832_ex31-1.htm Edgar Link pending
v464832_ex31-2.htm Edgar Link pending
v464832_ex32-1.htm Edgar Link pending